GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Constellation Pharmaceuticals Inc (NAS:CNST) » Definitions » Asset Turnover

Constellation Pharmaceuticals (Constellation Pharmaceuticals) Asset Turnover : 0.00 (As of Mar. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Constellation Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Constellation Pharmaceuticals's Revenue for the three months ended in Mar. 2021 was $0.00 Mil. Constellation Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2021 was $422.26 Mil. Therefore, Constellation Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2021 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Constellation Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2021 was -40.68%. It is also linked to ROA % through Du Pont Formula. Constellation Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2021 was -37.96%.


Constellation Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Constellation Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Constellation Pharmaceuticals Asset Turnover Chart

Constellation Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
Asset Turnover
- - - - -

Constellation Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Constellation Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Constellation Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Constellation Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Constellation Pharmaceuticals's Asset Turnover falls into.



Constellation Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Constellation Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=0/( (399.13+441.854)/ 2 )
=0/420.492
=0.00

Constellation Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2021 )/( (Total Assets (Q: Dec. 2020 )+Total Assets (Q: Mar. 2021 ))/ count )
=0/( (441.854+402.659)/ 2 )
=0/422.2565
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Constellation Pharmaceuticals  (NAS:CNST) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Constellation Pharmaceuticals's annulized ROE % for the quarter that ended in Mar. 2021 is

ROE %**(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=-160.288/394.0215
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-160.288 / 0)*(0 / 422.2565)*(422.2565/ 394.0215)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0717
=ROA %*Equity Multiplier
=-37.96 %*1.0717
=-40.68 %

Note: The Net Income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Constellation Pharmaceuticals's annulized ROA % for the quarter that ended in Mar. 2021 is

ROA %(Q: Mar. 2021 )
=Net Income/Total Assets
=-160.288/422.2565
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-160.288 / 0)*(0 / 422.2565)
=Net Margin %*Asset Turnover
= %*0
=-37.96 %

Note: The Net Income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Constellation Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Constellation Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Constellation Pharmaceuticals (Constellation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
215 First Street, Suite 200, Cambridge, MA, USA, 02142
Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.
Executives
Emma Reeve officer: Chief Financial Officer C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Karen Valentine officer: See Remarks C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421
Mark A Goldsmith director, 10 percent owner 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Humphrey officer: Chief Medical Officer C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Elizabeth Trehu director C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
James E Audia director 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142
Adrian Senderowicz officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jigar Raythatha director, officer: See Remarks C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Patrick Trojer officer: Chief Scientific Officer 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Ponoi Management, Llc 10 percent owner, other: General Partner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
David V Goeddel 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158

Constellation Pharmaceuticals (Constellation Pharmaceuticals) Headlines